全文获取类型
收费全文 | 1720407篇 |
免费 | 129356篇 |
国内免费 | 6516篇 |
专业分类
耳鼻咽喉 | 22040篇 |
儿科学 | 56083篇 |
妇产科学 | 46668篇 |
基础医学 | 243955篇 |
口腔科学 | 49320篇 |
临床医学 | 155319篇 |
内科学 | 335994篇 |
皮肤病学 | 38974篇 |
神经病学 | 132557篇 |
特种医学 | 65026篇 |
外国民族医学 | 259篇 |
外科学 | 260447篇 |
综合类 | 45268篇 |
一般理论 | 537篇 |
预防医学 | 125592篇 |
眼科学 | 41091篇 |
药学 | 127167篇 |
30篇 | |
中国医学 | 6178篇 |
肿瘤学 | 103774篇 |
出版年
2021年 | 12620篇 |
2019年 | 14902篇 |
2018年 | 21256篇 |
2017年 | 16457篇 |
2016年 | 17575篇 |
2015年 | 20637篇 |
2014年 | 28420篇 |
2013年 | 39867篇 |
2012年 | 55617篇 |
2011年 | 58533篇 |
2010年 | 34704篇 |
2009年 | 32245篇 |
2008年 | 53554篇 |
2007年 | 56852篇 |
2006年 | 57184篇 |
2005年 | 54546篇 |
2004年 | 52007篇 |
2003年 | 49368篇 |
2002年 | 47357篇 |
2001年 | 92490篇 |
2000年 | 94303篇 |
1999年 | 77611篇 |
1998年 | 19355篇 |
1997年 | 16916篇 |
1996年 | 16898篇 |
1995年 | 17091篇 |
1994年 | 15617篇 |
1993年 | 14279篇 |
1992年 | 57603篇 |
1991年 | 55523篇 |
1990年 | 53164篇 |
1989年 | 50907篇 |
1988年 | 46272篇 |
1987年 | 45063篇 |
1986年 | 42319篇 |
1985年 | 40057篇 |
1984年 | 29360篇 |
1983年 | 24897篇 |
1982年 | 13883篇 |
1979年 | 25501篇 |
1978年 | 17541篇 |
1977年 | 14862篇 |
1976年 | 13836篇 |
1975年 | 14520篇 |
1974年 | 17613篇 |
1973年 | 16918篇 |
1972年 | 15667篇 |
1971年 | 14436篇 |
1970年 | 13417篇 |
1969年 | 12509篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
3.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
4.
Rozhkov V. P. Trifonov M. I. Soroko S. I. 《Neuroscience and behavioral physiology》2022,52(3):383-394
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia... 相似文献
5.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
6.
7.
8.
Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4+ T and CD8+ T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections. 相似文献
9.
10.
目的 分析重症患者营养支持期间发生再喂养综合征的危险因素,为早期识别及预防再喂养综合征提供参考。方法 检索中国知网、万方数据库、中华医学期刊全文数据库、中国生物医学文献数据库、维普网、PubMed、Embase、Cochrane Library、Elsevier关于重症患者再喂养综合征危险因素的文献,检索时间为各数据库建库至2021年12月,采用RevMan5.3进行Meta分析。结果 纳入13篇文献,包括2 519例患者,其中病例组793例,对照组1 726例;Meta分析合并效应值显示年龄(WMD=4.69)、APACHEⅡ评分(WMD=2.50)、BMI(WMD=-0.94)、白蛋白水平(OR=4.61)、前白蛋白水平(WMD=-53.46)、基线血镁水平(WMD=-0.05)、基线血钾水平(WMD=0.18)、基线血磷水平(WMD=-0.07)是重症患者发生再喂养综合征的危险因素(P<0.05,P<0.01)。结论 基于现有证据,重症患者再喂养综合征的危险因素包括年龄、APACHEⅡ评分、营养状况及电解质水平,医护人员需密切关注重症患者营养支持期间能量、蛋白质及电解... 相似文献